Rayence Co. Ltd (228850) - Total Liabilities

Latest as of June 2026: ₩29.87 Billion KRW ≈ $20.24 Million USD

Based on the latest financial reports, Rayence Co. Ltd (228850) has total liabilities worth ₩29.87 Billion KRW (≈ $20.24 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Rayence Co. Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Rayence Co. Ltd - Total Liabilities Trend (2015–2025)

This chart illustrates how Rayence Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 228850 current and non-current assets.

Rayence Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Rayence Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Railcare Group AB (publ)
ST:RAIL
Sweden Skr846.25 Million
Da Ming International Holdings Limited
F:DM7
Germany €9.59 Billion
Ares International Corp
TW:2471
Taiwan NT$594.70 Million
Polaris Office Corp
KQ:041020
Korea ₩132.65 Billion
Hyundai Livart Furniture Co Ltd
KO:079430
Korea ₩358.54 Billion
Super Dragon Technology Co Ltd
TW:9955
Taiwan NT$1.80 Billion
JOONGANG DNM Co.Ltd
KQ:051980
Korea ₩22.80 Billion
PolyPid
NASDAQ:PYPD
USA $11.33 Million

Liability Composition Analysis (2015–2025)

This chart breaks down Rayence Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Rayence Co. Ltd balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 11.99 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.12 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.11 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Rayence Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Rayence Co. Ltd (2015–2025)

The table below shows the annual total liabilities of Rayence Co. Ltd from 2015 to 2025.

Year Total Liabilities Change
2025-12-31 ₩23.85 Billion
≈ $16.16 Million
-2.84%
2024-12-31 ₩24.55 Billion
≈ $16.64 Million
-33.09%
2023-12-31 ₩36.69 Billion
≈ $24.86 Million
-1.51%
2022-12-31 ₩37.25 Billion
≈ $25.24 Million
-9.63%
2021-12-31 ₩41.22 Billion
≈ $27.94 Million
+12.78%
2020-12-31 ₩36.55 Billion
≈ $24.77 Million
-3.24%
2019-12-31 ₩37.78 Billion
≈ $25.60 Million
+96.06%
2018-12-31 ₩19.27 Billion
≈ $13.06 Million
-2.74%
2017-12-31 ₩19.81 Billion
≈ $13.42 Million
-20.56%
2016-12-31 ₩24.94 Billion
≈ $16.90 Million
-26.79%
2015-12-31 ₩34.06 Billion
≈ $23.08 Million
--

About Rayence Co. Ltd

KQ:228850 Korea Medical Devices
Market Cap
$77.85 Million
₩114.88 Billion KRW
Market Cap Rank
#20287 Global
#1091 in Korea
Share Price
₩7300.00
Change (1 day)
+2.53%
52-Week Range
₩4895.00 - ₩7700.00
All Time High
₩20930.72
About

Rayence Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and sale of digital X-ray detector products for dental, medical, veterinary, and industrial sectors in South Korea, the United States, Mexico, China, and internationally. The company offers TFT/CMOS X-ray detectors for general radiography, C-arm/RF, mammography, and radiotherapy; and CMOS/Super IGZO TFT/a-… Read more